false
0001447028
0001447028
2025-09-09
2025-09-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported): September 9, 2025
Arbutus Biopharma Corporation
(Exact name of registrant as specified in its charter)
| British Columbia, Canada |
|
001-34949 |
|
98-0597776 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
701 Veterans Circle
Warminster, Pennsylvania |
|
18974 |
| (Address of principal executive offices) |
|
(Zip Code) |
(267) 469-0914
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Shares, without par value |
|
ABUS |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405
of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of
the Exchange Act. o
Item 8.01. Other Events.
On September 9, 2025, the U.S. District Court for the District of New Jersey
issued a claim construction ruling in the lawsuit brought by Arbutus Biopharma Corporation and its licensee Genevant Sciences against
Pfizer Inc. and BioNTech SE (Pfizer/BioNTech) seeking damages for infringement of U.S. Patent Nos. 9,504,561, 8,492,359, 11,141,378, 11,298,320
and 11,318,098 in the manufacture and sale of Pfizer/BioNTech’s COVID-19 mRNA-based vaccines. A copy of the Court’s claim
construction order and opinion is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number |
|
Description |
| 99.1 |
|
Claim Construction Order and Opinion, dated September 9, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Arbutus Biopharma Corporation |
| |
|
| Date: September 10, 2025 |
By: |
/s/ Tuan Nguyen |
| |
Name: |
Tuan Nguyen |
| |
Title: |
Chief Financial Officer |
